FOR IN VITRO AND PRE-CLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE
Growth Hormone

Ipamorelin 10mg

10mg selective GHS research peptide

From€39.00
In Stock · Ships within 48h
Reviews coming soonBe among the first to share your research experience.
Download Certificate of Analysis
  • EU Dispatch
  • CoA Included — Every Batch
  • Discreet Packaging
Purity≥98% HPLC
FormLyophilised Powder
Storage2–8°C
OriginEuropean Stock
DispatchWithin 48h
SKUUL-IPA-10MG
≥98% PureHPLC verified
HPLC TestedDual identity check
EU DispatchShips within 48h
CoA Incl.Every batch
Research Profile

Why Ipamorelin Fascinates Researchers

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue (GHS) — one of the most selective and well-characterised agonists of the growth hormone secretagogue receptor (GHSR-1a, the ghrelin receptor) available as a research tool. First reported by Raun and colleagues at Novo Nordisk in 1998, it was designed specifically to maximise GH-releasing potency while minimising the off-target effects that complicated earlier generation secretagogues.

The Ghrelin Receptor & GH Secretagogue Pharmacology

The growth hormone secretagogue receptor (GHSR-1a) is a seven-transmembrane G protein-coupled receptor that is constitutively active and serves as the receptor for endogenous ghrelin. It is expressed highly on pituitary somatotrophs, where its activation stimulates GH secretion through a mechanism distinct from and complementary to the GHRH receptor pathway. GHSR agonism increases intracellular calcium via Gq/phospholipase C signalling and, through distinct mechanism, amplifies cAMP responses to concurrent GHRHR activation — creating a pharmacological synergy between the two GH secretagogue systems.

Selectivity Profile & Preclinical Evidence

What distinguishes ipamorelin from earlier GH secretagogues (GHRP-2, GHRP-6, hexarelin) is its highly selective GH-releasing profile. Raun et al. demonstrated in 1998 that ipamorelin had negligible effects on ACTH, cortisol, or prolactin secretion at GH-releasing doses — a selectivity profile markedly superior to GHRP-2 and GHRP-6, which produce significant ACTH and cortisol elevations. This specificity makes ipamorelin a cleaner pharmacological tool for research applications where selective GHSR activation without adrenocortical stimulation is required.

Johansen and colleagues demonstrated in 1999 that ipamorelin administration in young female rats produced significant increases in longitudinal bone growth velocity (tibial width, metatarsal length) comparable to GH itself — validating the functional consequence of GHSR agonism in a growth-relevant endpoint, with dose-dependent effects on IGF-1 levels consistent with GH-mediated hepatic IGF-1 stimulation.

Comparative Secretagogue Research

The availability of ipamorelin alongside related compounds (GHRP-2, GHRP-6, hexarelin, MK-677) provides researchers with a pharmacological toolkit for dissecting GH secretagogue receptor pharmacology. Comparative studies exploiting differences in receptor selectivity and downstream signalling can help identify which GH axis effects are attributable to GHSR signalling per se versus off-target receptor interactions present with less selective compounds.

This content is for informational purposes only and reflects the state of preclinical research. It does not constitute medical advice, endorsement of human use, or therapeutic claims of any kind.

Manufacturing Standards

Our Quality Commitment

HPLC Verified

Purity confirmed by High-Performance Liquid Chromatography at an accredited EU laboratory.

≥98% Purity

Every batch meets or exceeds 98% purity. CoA available for verification before dispatch.

Batch Traceability

Each vial is traceable to its synthesis batch, testing date, and analytical records.

Cold Chain Storage

European stock stored at optimal temperature from synthesis to dispatch.

48h EU Dispatch

Orders ship from EU stock within 48 hours with discrete, temperature-appropriate packaging.

CoA Included

Certificate of Analysis issued for every batch, available for download on request.

Download CoA for Ipamorelin 10mg
Peer-Reviewed Literature

Key Scientific Studies

Peer-reviewed research supporting Ipamorelin investigation.

[01]
Raun K, Hansen BS, Johansen NL, et al. (1998) — European Journal of Endocrinology

“Ipamorelin, the first selective growth hormone secretagogue”

Founding pharmacological characterisation of ipamorelin, establishing its potency and selectivity as a GHSR agonist. The study demonstrates GH-releasing activity comparable to GHRP-2 and GHRP-6 alongside a dramatically superior selectivity profile — minimal effects on ACTH, cortisol, prolactin, or FSH at GH-releasing doses — defining ipamorelin as the first selective growth hormone secretagogue.

View on PubMed
[02]
Johansen PB, Nowak J, Skjaerbaek C, et al. (1999) — Growth Hormone & IGF Research

“Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats”

In vivo characterisation of ipamorelin's effects on skeletal growth in young rats. The study reports dose-dependent increases in tibial longitudinal bone growth velocity and metatarsal weight comparable to recombinant GH, confirming that GHSR agonism is sufficient to drive GH-mediated skeletal growth responses and validating ipamorelin as a functional GH secretagogue in vivo.

View on PubMed
[03]
Zdravkovic M, Christiansen JS, Raun K, et al. (2000) — Growth Hormone & IGF Research

“Characterisation of the pharmacokinetics of ipamorelin in young male and female volunteers”

Human pharmacokinetics study characterising ipamorelin's absorption, distribution, and elimination profile in healthy volunteers. Key findings include rapid absorption, short plasma half-life consistent with its peptide structure, and dose-proportional GH-releasing pharmacodynamics — data that establish the pharmacokinetic framework for designing ipamorelin-based research protocols.

View on PubMed

All studies referenced are independent third-party research. UNIK LAB makes no claims regarding the therapeutic efficacy of any compound and does not represent or endorse the conclusions of cited studies. All referenced research was conducted under controlled laboratory or clinical conditions; results may not be predictive of effects in other experimental contexts.

Common Questions

Research FAQ

Answers to the most frequently asked questions about Ipamorelin.

Same Category

Similar Compounds

Other Growth Hormone research compounds from our catalogue.

Your Longevity Research Guide Awaits

Subscribe to receive new compound profiles, CoA updates, and curated research digests — delivered directly to your inbox.